CN Patent

CN102307875A — 吡咯并嘧啶基axl激酶抑制剂

Assigned to Astex Pharmaceuticals Inc · Expires 2012-01-04 · 14y expired

What this patent protects

式(I)表示的化合物可用于治疗受Axl激酶介导的或与其有关(至少是部分地)的疾病，例如癌症。该化合物可被配制成可药用的组合物，用于施用给有需要的对象。

USPTO Abstract

式(I)表示的化合物可用于治疗受Axl激酶介导的或与其有关(至少是部分地)的疾病，例如癌症。该化合物可被配制成可药用的组合物，用于施用给有需要的对象。

Drugs covered by this patent

quizartinib-dihydrochloride (QUIZARTINIB DIHYDROCHLORIDE)

Patent Metadata

Patent number: CN102307875A
Jurisdiction: CN
Classification: —
Expires: 2012-01-04
Drug substance claim: No
Drug product claim: No
Assignee: Astex Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.